Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016

  • ID: 3775402
  • Report
  • 71 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Actelion Ltd
  • AstraZeneca Plc
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016

Summary

‘Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Review, H1 2016’, provides in depth analysis on Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted pipeline therapeutics.

The report provides comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)
- The report reviews Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Actelion Ltd
  • AstraZeneca Plc
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Overview

Therapeutics Development

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Stage of Development

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Therapy Area

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Indication

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Products under Development by Companies

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Companies Involved in Therapeutics Development

Actelion Ltd

Arena Pharmaceuticals, Inc.

AstraZeneca Plc

Celgene Corporation

GlaxoSmithKline Plc

Meiji Seika Pharma Co., Ltd.

Novartis AG

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Drug Profiles

AKP-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APD-334 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cenerimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-9531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NIBR-0213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ozanimod hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ponesimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

siponimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1PR1 for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize S1PR1 for Ulcerative Colitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Dormant Projects

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Discontinued Products

Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) - Featured News & Press Releases

May 04, 2016: Study Shows Ozanimod as Effective in Treating Ulcerative Colitis

Mar 18, 2016: Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial

Feb 18, 2016: Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS

Jan 08, 2016: Suzhou Connect Biopharma Reports Positive Phase 1b Result for Novel S1P1 Modulator CBP-307 for Autoimmune Diseases

Dec 14, 2015: Akaal Pharma Announces Superior Safety and Comparable Efficacy of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 as Compared to Gilenya (Fingolimod) for the Treatment of Multiple Sclerosis

Dec 14, 2015: US Patents Issued to Akaal Pharma on S1P1 Receptor Modulators Useful for the Treatment of Autoimmune and Inflammatory Diseases

Oct 26, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week

Oct 19, 2015: Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at ACG Plenary Session

Sep 01, 2015: MS Trial Alert: Investigators Recruiting Worldwide for Phase III Clinical Trial of Oral Ponesimod

Jul 30, 2015: Suzhou Connect Biopharma Reports Positive Phase 1a Results for CBP-307, a Novel, Orally-active S1P1 Modulator for Autoimmune Diseases

Jul 29, 2015: Arena Pharmaceuticals Initiates a Phase 2 Clinical Trial of APD334, its S1P1 Receptor Modulator for Autoimmune Diseases

Jul 09, 2015: Suzhou Connect Biopharma Announces Patent Issuance Covering CBP-307 - a Clinical-stage Second Generation S1P1 Immune Modulator

Jul 01, 2015: Akaal Pharma, Australia extends collaboration with GVK BIO for formulations development services to support Phase 2 Clinical studies for Topical Treatment of Psoriasis

Jun 25, 2015: New Data Supporting Gradual Up-Titration Of Ponesimod To Mitigate First-Dose Cardiodynamic Effects To Be Presented At Eacpt 2015

Jun 16, 2015: Akaal Pharma Receives Approval to Initiate Phase 2 Clinical Trial for the Topical Treatment of Psoriasis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Actelion Ltd, H1 2016

Pipeline by Arena Pharmaceuticals, Inc., H1 2016

Pipeline by AstraZeneca Plc, H1 2016

Pipeline by Celgene Corporation, H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016

Pipeline by Novartis AG, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Actelion Ltd
  • AstraZeneca Plc
  • Celgene Corporation
  • GlaxoSmithKline Plc
  • Novartis AG
  • MORE
According to our recently published report 'Sphingosine 1-Phosphate Receptor 1– Pipeline Review, H1 2016'; Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies.

Furthermore, the publisher says; Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.

The report 'Sphingosine 1-Phosphate Receptor 1– Pipeline Review, H1 2016' outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (S1P Receptor 1 or Endothelial Differentiation G-Protein Coupled Receptor 1 or Sphingosine 1-Phosphate Receptor Edg-1 or CD363 or S1PR1 or CHEDG1 or EDG1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 3 and 6 respectively.
Note: Product cover images may vary from those shown
5 of 6
Actelion Ltd
Arena Pharmaceuticals, Inc.
AstraZeneca Plc
Celgene Corporation
GlaxoSmithKline Plc
Meiji Seika Pharma Co., Ltd.
Novartis AG
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll